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Abstract The present study focuses on the application of
a therapeutic strategy in patients with chronic severe lower
limb ischaemia using a plasmid vector encoding the vas-
cular endothelial growth factor (phVEGF165). It has been
shown that VEGF promotes neo-vascularization and blood
vessel network formation and thus might have the ability to
improve blood-ﬂow at the level of the affected limbs.
However, little information is available regarding the
necessary level of expression of VEGF and its possible
related adverse effects. We have subcloned VEGF165 iso-
form into pCMV-Script expression vector (Stratagene)
under the control of the CMV promoter. Three patients
with chronic ischaemia of the lower limb, considered as not
suitable for surgical re-vascularization, received intramus-
cular injection with 0.5 ml saline solution containing 1011
copies of VEGF165 plasmid. The clinical evolution has
been monitored by angiography and estimated by walking
time on the rolling carpet (Gardner protocol). Two months
after therapy, all three patients showed complete relief of
rest pain, improvement of ischaemic ulcer lesions and in-
creased walking distance on the rolling carpet most prob-
ably due to appearance of newly formed collateral vessels.
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Abbreviations
CMV cytomegalovirus
PCR Polymerase chain reaction
RT-PCR Real time PCR
FLK 1 fetal liver kinase 1 (VEGF receptor 2)
FLT 1 Fms-like tyrosine kinase 1 (VEGF receptor 1)
KDR kinase insert domain receptor (a type III
receptor tyrosine kinase)
VEGF Vascular endothelial growth factor
VEGF165 VEGF isoform with 165 aminoacids
Introduction
Cardiovascular disease represents a major cause of mor-
bidity and mortality worldwide with atherosclerosis being
one of the main pathological mechanism involved. Previ-
ous studies have shown a strong relationship between
atherosclerosis promoting factors (high blood pressure,
diabetes mellitus, smoking, hyperlipidemia, sedentariness)
and the development of the peripheral ischaemic disease
(Brown et al. 1972; Helmlinger et al. 2000). This condition
affects mainly the arteries of the lower limb leading to
decreased blood ﬂow with subsequent ischaemic lesions.
Severe lower limb ischaemia accounts for 70% of the 150
million lower limb amputations (Eskelinen et al. 2004).
Conventional treatment of lower limb ischaemia has two
main components: conservative and interventional/surgical
therapy. The conservative approach includes modiﬁcation
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DOI 10.1007/s11568-007-9006-5of the risk factors (smoking cessation, control of glycaemia
and blood pressure, decrease of lipid levels) associated
with anti-platelet therapy (aspirin). Ischaemic rest pain is
alleviated with pain medication ad libitum associated with
correction of any underlying systemic cause of low blood
ﬂow (such as cardiac failure). Patients not responding to
conservative therapy are candidates for surgical treatment,
revascularization (angioplasty, stent placement and bypass
surgery with autologous veins or prosthetic conduits) and
amputation.
Gene therapy with vascularization promoting factors
(VEGF, angiopoietins, hepatocyte growth factor) has been
established as a potential strategy for inducing re-vascu-
larization in patients with severe lower limb ischaemia
(Isner et al. 1996; Isner et al. 1998; Thurston et al. 2000;
Rajagopalan et al. 2001; Shyu et al. 2003; Gerritsen
2005).
In contrast to other polypeptide mitogens, VEGF (also
called vascular promoting factor) is primarily active on
vascular endothelial cells. Analysis of VEGF transcripts by
PCR, DNA cloning (Tischer et al. 1991) or RT-PCR
(Poltorak et al. 1997) identiﬁed 5 isoforms with 121, 141,
145, 165 and 189 amino acids. VEGF controls blood vessel
formation and permeability by interacting with 2 endo-
thelial tyrosine kinase receptors FLT 1 and KDR/FLK 1.
VEGF165 seems to be the predominant form and has a
speciﬁc receptor (VEGF165R) identical to neuropilin-1
(Bacic et al. 1995; Soker et al. 1998).
VEGF expression is regulated by the level of glycaemia
and oxygen, both hypoglycaemia and hypoxia being strong
inducers of VEGF synthesis (Helmlinger et al. 2000; Dantz
et al. 2002). Reduced tissue level of nutrients and oxygen
are common features of peripheral ischaemic disease, thus
providing a rationale for using VEGF in the treatment of
chronic lower limb ischaemia.
Nevertheless, VEGF therapy for lower limb ischaemia is
still controversial and very few data are known about the
level of expression necessary in order to achieve a thera-
peutic effect and, even more, about the related side effects.
Recent reports indicated that transgenic (Thurston et al.
1999) or adenoviral (Thurston et al. 2000) over-expression
of VEGF resulted in formation of leaky vessels in labora-
tory animals (Isner et al. 1998; Blau and Banﬁ 2001) and
that plasmid-based intramuscular VEGF gene transfer led
to transient oedema in human subjects (Baumgartner et al.
2000). Combinations of VEGF with other growth factors
(such as with angiopoeitin-1, hepatocyte growth factor)
have been tested as alternative strategies to promote new
vessel growth and limit the oedema associated with VEGF
(Gerritsen 2005).
The present study evaluates the clinical outcome (rest
pain, claudication, evolution of ischaemic ulcerative le-
sions, walking distance on rolling carpet as assessed by
Gardner protocol) and angiographically assesses the for-
mation of new blood vessels after VEGF165 gene therapy in
patients with severe chronic lower limb ischaemia.
Methods
Study design
We designed a single blind study aiming at analysing the
possible effect of VEGF165 muscle overexpression on the
clinical evolution of the patients diagnosed with lower limb
severe chronic ischaemia unresponsive to classical treat-
ment.
The study protocol was approved by the Ethics Com-
mittee of the ‘‘Victor Babes’’ University of Medicine and
Pharmacy from Timisoara, Romania.
Patients
Patients (35–53 years old) with severe lower limb ischae-
mia admitted at the Institute for Cardiovascular Disease
from Timisoara, Romania were screened for this study
based on speciﬁc clinical and laboratory investigations. We
focused our study on lower limb ischaemia patients for
whom the amputation was the only therapeutic alternative
left.
Inclusion criteria
(1) Evidence of severe lower limb ischaemia, including
rest pain (not responding to analgesic therapy) and
skin ulcerous lesions (that had not healed after at least
1 month of conventional therapy).
(2) Angiography showing obliteration of limb arteries.
(3) Unsuitability for surgical or percutaneous revascu-
larization based on usual practice standards.
Exclusion criteria
(1) Women of fertile age undergoing treatment with an-
tiplatelet or thrombolytic medication started less than
1 month prior to the onset of the procedure
(2) Patients under therapy with prostaglandins (less than
3 months prior to the onset of the procedure) and
immunosuppressants.
(3) History of osteomyelitis, coronary diseases, stroke,
renal insufﬁciency, hepatitis, diabetes and prolifera-
tive diabetic retinopathy, malignancy.
(4) Admission to a recuperative care program based on
physical therapy.
All patients have undertaken screening tests (blood,
urine, stool exam, chest X-ray, abdominal ultrasonography,
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123ophthalmologic examination) prior to admission into the
program.
Patients gave their written informed consent for being
taken into the study and subjected to the therapeutic pro-
cedure.
Patient monitorisation after procedure
We designed a two step follow-up protocol meant to
accurately monitor the changes in the health status of our
patients and to allow a prompt response in case of a life
threatening situation. The early phase spanned the ﬁrst
three days post-therapy and consisted of a close clinical
monitoring of general health status, evolution of the
ischaemia symptoms and the appearance of possible side-
effects of therapy (oedema of the cured lower limb, fever,
increased levels of acute phase reactants). The second step
of monitorisation phase scheduled clinical tests (walking
test, ankle-brachial index), control angiography, investi-
gation of acute phase reactant levels, ophthalmologic
examination, routine hematology and blood chemistry, and
urinalysis at two, four and eight weeks post procedure.
VEGF165 vector construction and multiplication
Human Lung cDNA from Clontech was used for multi-
plication and insertion of the VEGF165 gene (GenBank
accession no. AB021221) into the pCVM-Script mamma-
lian expression vector (Stratagene) under the control of the
cytomegalovirus promoter/enhancer. The VEGF165 speciﬁc
cDNA was ampliﬁed by PCR using the following primers:
5¢-ttggccgaattcatgaactttctgctgtcttgggt-3¢ and 5¢-
tttggccctcgagtcaccgcctcggcttgtcac-3¢. The primers contain
the restriction sites for EcoRI and XhoI enzymes, subse-
quently used for insertion of the VEGF165 cDNA into the
expression vector.
PCR reaction was carried out in a ﬁnal volume of 20 ll
containing 50 ng genomic DNA, 1x HotStar Taq DNA
Polymerase buffer with 1.5 mM MgCl2 (Qiagen), 4 pmo-
les of each primer, 1UI HotStar Taq DNA Polymerase
(Quiagen) and 2.5 mM dNTPs. PCR ampliﬁcation condi-
tions were as follows: initial denaturation and HotStar Taq
Polymerase activation at 95 C for 15 min; 35 cycles of
30 s at 95 C, 30 s at 62 C with 45 s extension at 72 C;
ﬁnal extention of 7 min at 72 C. In order to verify the
nucleotidic sequence of the obtained VEGF165 speciﬁc
cDNA, the amplicons were subsequently bidirectionally
sequenced using the BigDye Terminator sequencing kit
(Applied Biosystems) according to the manufacturer’s
instructions on an ABI Prism 310 capillary electrophoresis
device (Applied Biosystems). The obtained sequence was
compared with the GenBank reference sequence with the
aid of the Sequencing Analysis v3.1 (Applied Biosystems)
software.
The VEGF165 cDNA was cut with EcoRI and XhoI
(Promega) followed by ligation using the T4 DNA Ligase
System (Promega) puriﬁed from agarose gel with MiniE-
lute Gel Extraction Kit (Qiagen) and introduced into
pCMV-Script liniarised vector using the T4 DNA Ligase
System (Promega).
For transformation and selection of clones we used
XL1-Blue Supercompetent Cells (Stratagene) cultured at
37 C on LB Agar plates containing kanamicin. In order to
verify the presence of the insert, the selected colonies were
tested by PCR and sequenced as described above.
The colonies containing the correct insert were then
cultured overnight at 37 C on LB Broth liquid medium.
Vector puriﬁcation was performed using the GenElute HP
Plasmid Maxiprep Kit (Sigma) following the manufac-
turer’s protocol; purity and quantity of the obtained vector
were measured by UV spectrometry. The measured 260/
280 ratio showed no protein contamination, being con-
stantly over 1.9, and the quantity obtained was around
1.3 · 10
13 copies of vector.
VEGF165 vector conditioning and administration
The whole quantity of puriﬁed vector was brought to 50 ml
in sterile Falcon tubes with 0.9% NaCl sterile perfusion
solution. The obtained solution was then subjected to a
standard sterility veriﬁcation protocol, by cultivating 1 ml
in bullion medium for 5 days followed by subsequent
cultivation on aerobe and anaerobe speciﬁc media,
respectively. No bacterial growth was observed in any
case.
Administration was performed by intramuscular injec-
tion of a total of 3 mls saline solution containing 10
11/ml
copies of vector into the thigh (6 injections) and calf
muscles (10 injections) (at 3–4 cm intervals), on a trajec-
tory with potential angiogenic beneﬁt, as judged by the
most recent angiography of the ischaemic leg (Fig. 1).
Results
Among the 39 patients screened we found 3 patients elli-
gible for the study; the remaining 36 patients met the cri-
teria for interventional revascularization.
The study group included 1 male and 2 females with
ages ranging from 35 to 53 years old; the clinical data of
the patients (prior and post therapeutic intervention) are
shown in Table 1.
Following gene therapy all patients showed an initial
temporary increase of the acute phase reactant levels (C-
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123reactive protein) with peaks within the ﬁrst 6–48 h,
reaction which was considered normal after intramuscular
administration of the plasmid vectors (Fig. 2). No local
oedema was observed in any of the patients at the sites of
injection. One patient (number 3 in Table 1) developed a
short episode of fever (38.6 C) at 2 h after injection, but
this was completely controlled by administration of
100 mg hydrocortisone hemisuccinate.
Erythrocite sedimentation rate decreased signiﬁcantly
in patient 1 with a minimum at 48 h. In the case of the
other 2 patients (and in contrast with the C-reactive
proteine levels) we observed minimal increases of the
sedimentation rates with peaks at 24 h and 48 h, respec-
tively (Fig. 3).
Patients were followed-up by physical examination
(including change in ischemic ulcers), walking test,
control angiography, measurements of ankle-brachial
index, acute phase reactant levels at 14 days, 1 month
and 2 months after the therapeutic procedure was per-
formed.
All patients showed a marked diminution of the resting
pain in the ﬁrst 2 weeks with consecutive decrease of use
of analgesics; this improvement in resting pain was main-
tained for the following weeks.
Examination of the lower limb showed signs of im-
proved nutrition of the tissues, with increased local tem-
perature and reduction of the area of ulcerative lesions.
Both patient number 1 and number 2 presented with
Fig. 1 The injection sites
Table 1 Clinical and angiographic ﬁndings before and after VEGF gene therapy
Clinical history and ﬁndings before gene therapy Outcomes after gene therapy
(2 months)
No. Gender Age
(years)
Diagnosis Signs/
symptoms
Angiographic ﬁndings Signs/symptoms Angiographic
ﬁndings
1 Female 46 Thromboangiitis
obliterans; critical
ischaemia of the left
foot
Claudication at
200 m,
resting pain,
toe gangrene
(digits IV–V)
Complete occlusion of the
superﬁcial femoral artery,
without blood supply in the
popliteal artery through collateral
vessels, perfusion only in the
distal half of the peroneal artery
Claudication at
350 m, resting
pain decreased,
gangrene area
reduced (digit V)
No detectable
changes
2 Female 35 Chronic obliterative
arteriopathy of the right
lower limb, stage II B;
critical ischaemia of the
right foot
Claudication at
150 m,
resting pain,
toe gangrene
(digit I)
Occlusion in the proximal region of
the right anterior tibial artery,
occlusion in the middle region of
the posterior tibial artery
Claudication at
450 m, resting
pain decreased,
gangrene area
reduced
No detectable
changes
3 Male 53 Chronic obliterative
arteriopathy of the left
lower limb, stage II B
Claudication at
50 m, resting
pain
Chronic bilateral occlusion of the
superﬁcial femoral artery,
occlusion of the left popliteal
artery and left calf arteries.
Claudication at
200 m, resting
pain decreased
Visible new
formed
collateral
vessels at
the level of
the calf
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123incipient ischaemic gangrene at the beginning of the study
and both showed a signiﬁcant decrease in the area of
gangrene after therapy (see Table 1 and Fig. 4).
All 3 patients showed signiﬁcant improvement of the
performance in the walking test at 2 months after thera-
peutic intervention (Fig. 5). The ankle-brachial index did
not show signiﬁcant changes in any of the three patients
suggesting that the central blood-ﬂow axis in the calf was
not signiﬁcantly modiﬁed (data not shown).
Control angiographies at two weeks, one months and
2 months after gene transfer were negative for signs of
progression of atherosclerosis or neo-vascularization. In
one case (patient number 3 in Table 1) we were able to
detect on the angiography performed two months after the
procedure a ﬁne, subtle network of new collateral blood
vessels at the level of the calf (Fig. 6).
Further assessment of the clinical and angiographic
status will be performed at 6 months interval in the future.
Discussion
Patients with chronic severe lower limb ischaemia classi-
ﬁed as not suitable for conventional revascularization
therapy (so-called ‘‘no-option patients’’) represent 10–15%
of all patients with peripheral artery disease and usually
receive only conservative management such as pain control
and vasodilators (Wolfe 1986; Albers et al. 1992). Both the
prognosis and quality of life for these patients are poor. Up
to now, no pharmacological therapy has been shown to
improve the natural history of severe lower limb ischaemia
(Stapanavatr et al. 2004).
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123Collateral vessels could provide an important blood ﬂow
in the case of arterial occlusion. Angiogenic gene therapy
aims to increase collateral vessels in ischaemic areas by the
injection of angiogenic factor. Consequently, the limb
ischaemia is reduced and the clinical symptoms such as
claudication, resting pain, evolution of ischaemic wounds
Fig. 4 Patient with chronic
lower limb ischaemia. Pictures
were taken on day 0 (left) and
2 months after VEGF gene
therapy (right)
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123are improved leading to a better prognosis for these pa-
tients. VEGF has been proved as a speciﬁc mitogen for
endothelial cells (Keck et al. 1989; Leung et al. 1989).
Experimental and clinical studies have reported that VEGF
could be an alternative treatment for patients with critical
limb ischaemia because it induces the formation of new
collateral vessel in ischaemic areas (Takeshita et al. 1994;
Isner et al. 1996; Isner et al. 1998; Shyu et al. 2003).
Given previous results on animal models, there are
concerns over the appearance of abnormal angiogenesis
associated with the use of angiogenic growth factors (Bacic
et al. 1995; Anghel et al. 2002). Studies in mice have
shown that while over-expression of VEGF induces the
growth of blood vessels, the capillaries are leaky, the tis-
sues are inﬂamed and the blood vessels have an abnormal
‘‘corkscrew-like’’ shape. To address this problem in hu-
mans VEGF alone should either be delivered over the long-
term, at the appropriate dose and time using regulatable
vectors, or transiently at low levels (Blau and Banﬁ 2001).
The results of a previous study have reported beneﬁcial
clinical effects for patients who received intramuscular
administration of VEGF gene-carrying plasmid
(phVEGF165)—this injection was repeated once at
4 weeks, resulting in a total of 4,000 lg phVEGF165
(Kusumanto et al. 2006).
Our study on short term effects of angiogenic therapy in
severe lower limb ischaemia suggests that muscle VEGF165
over-expression might constitute a promising therapeutic
approach. We ﬁnd signiﬁcant that all three subjects showed
an improved performance on the walking carpet, which
suggests an increase in blood supply of the lower limb
muscles. Surprisingly, the pressumed improvement in
collateral blood ﬂow was substantiated in only one case by
a control angyography at two months after the procedure,
with the appearance of a network of new collateral blood
vessels. We are tempted to attribute the lack of signs of
vascular neo-formation in the other two patients to the
limitations inherent to this method of investigation. Current
methods used to perform diagnostic contrast angiography
cannot provide images of arteries measuring <200 lmi n
diameter (Takeshita et al. 1997). Thus, conventional
angiographic techniques used in the present study may
have failed to depict the full extent of angiogenesis
achieved after gene therapy.
The most obvious result of our VEGF165 therapy study
is a marked decrease of the pain (both resting pain and
claudication, the use of antalgics) experienced by all three
patients. We have noticed that the decrease of pain was
more signiﬁcant compared to the resolution of gangrene. It
is possible that the decrease in ischaemic resting pain was
caused not only by increased blood ﬂow but also by
recovery from ischaemic neuropathy. It has been demon-
strated that over-expression of VEGF results in the resto-
ration of large- and small-ﬁber peripheral nerve function in
diabetic and ischaemic neuropathy models (Schratzberger
et al. 2000; Isner et al. 2001; Schratzberger et al. 2001;
Simovic et al. 2001; Veves et al. 2001).
We were not able to measure the levels of blood VEGF
neither before nor after gene transfer. However, it has been
reported that baseline plasma VEGF is highly variable and
there is a marginal or no increase after intramuscular
transfer of phVEGF165 (Freedman et al. 2002).
In conclusion, we describe the clinical evolution of three
patients with chronic severe lower limb ischaemia treated
with a single dose of intramuscular injection with naked
plasmid DNA encoding the 165-amino acid isoform of
VEGF. We show that excepting a transient increase of the
acute phase reactant levels and an isolated fever episode,
the procedure was well tolerated and showed no serious
side effects directly related to gene transfer. One study has
shown transient lower-extremity oedema in 52% of the
patients who received intramuscular gene transfer for
critical limb ischaemia. Development of oedema was
unrelated to the dose of phVEGF165 and the treatment was
typically limited to a brief course of oral diuretics
(Baumgartner et al. 2000). It is noteworthy in our study
that there was no evidence of oedema in patients trans-
fected with the human VEGF gene.
We are aware that both the number of patients included
in this study and the duration of the follow-up does not
allow us to draw deﬁnitive conclusions regarding the
beneﬁts, drawbacks and safety of such a procedure. Par-
ticularly weakening our results is the lack of a control
group. This is a direct result of the extremely low number
of patients matching the inclusion criteria; a placebo
‘‘group’’ of one patient would have not added a statistical
value to our study. None of the patients knew whether the
intramuscular injections contained naked VEGF165 plasmid
DNA or 0.9% NaCl. Given the low number of patients
included in our study, we consider that this approach pre-
vented a placebo bias.
Given the failure of previous conventional therapy we
are tempted to state that overexpression of VEGF at the
level of the thigh and calf muscles prevented the amputa-
tion, which would have been the only alternative left for
the three patients.
Larger (and with a longer-term follow-up) studies are
needed to assess the long term outcome (in terms of efﬁ-
cacy and safety) of VEGF-based therapy in patients with
severe chronic lower limb ischaemia.
Summary
Gene therapy with vascularization promoting factors
(VEGF, angiopoietins, hepatocyte growth factor) has been
established as a potential strategy for inducing re-vascu-
larization in patients with severe lower limb ischaemia.
The present study evaluates the clinical outcome (rest pain,
Genomic Med. (2007) 1:47–55 53
123claudication, evolution of ischaemic ulcerative lesions,
walking distance on rolling carpet as assessed by the
Gardner protocol) and angiographically assesses the for-
mation of new blood vessels after VEGF165 gene therapy in
3 patients with severe chronic lower limb ischaemia,
showing that intramuscular VEGF gene transfer represents
a promising therapeutic approach for patients who do not
respond to conventional therapy.
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